Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.775 HKD
−153.09 M HKD
43.38 M HKD
860.67 M
About CLOVER BIOPHARMACEUTICALS LTD
Sector
CEO
Joshua Liang
Headquarters
Shanghai
Website
Founded
2018
FIGI
BBG0135F03T5
Clover Biopharmaceuticals Ltd. engages in the research and development of biopharmaceutical products. It is a global clinical-stage biotechnology company which engages in developing novel vaccines and biologic therapeutic candidates. The firm's Trimer-Tag technology platform is a product development platform for the creation of novel vaccines and biologic therapies. The company was founded on October 31, 2018 and is headquartered in Shanghai, China.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 2197 is 0.280 HKD — it has decreased by −5.08% in the past 24 hours. Watch CLOVER BIOPHARMACEUTICALS LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange CLOVER BIOPHARMACEUTICALS LTD stocks are traded under the ticker 2197.
2197 stock has fallen by −6.67% compared to the previous week, the month change is a −15.15% fall, over the last year CLOVER BIOPHARMACEUTICALS LTD has showed a −58.82% decrease.
2197 reached its all-time high on Dec 13, 2021 with the price of 14.800 HKD, and its all-time low was 0.200 HKD and was reached on Sep 4, 2024. View more price dynamics on 2197 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
2197 stock is 5.36% volatile and has beta coefficient of 2.80. Track CLOVER BIOPHARMACEUTICALS LTD stock price on the chart and check out the list of the most volatile stocks — is CLOVER BIOPHARMACEUTICALS LTD there?
Today CLOVER BIOPHARMACEUTICALS LTD has the market capitalization of 342.48 M, it has decreased by −4.84% over the last week.
Yes, you can track CLOVER BIOPHARMACEUTICALS LTD financials in yearly and quarterly reports right on TradingView.
CLOVER BIOPHARMACEUTICALS LTD is going to release the next earnings report on Apr 1, 2025. Keep track of upcoming events with our Earnings Calendar.
2197 net income for the last half-year is −103.08 M HKD, while the previous report showed −852.56 M HKD of net income which accounts for 87.91% change. Track more CLOVER BIOPHARMACEUTICALS LTD financial stats to get the full picture.
No, 2197 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 387.00 employees. See our rating of the largest employees — is CLOVER BIOPHARMACEUTICALS LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CLOVER BIOPHARMACEUTICALS LTD EBITDA is −1.00 B HKD, and current EBITDA margin is −6.41 K%. See more stats in CLOVER BIOPHARMACEUTICALS LTD financial statements.
Like other stocks, 2197 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CLOVER BIOPHARMACEUTICALS LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CLOVER BIOPHARMACEUTICALS LTD technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CLOVER BIOPHARMACEUTICALS LTD stock shows the sell signal. See more of CLOVER BIOPHARMACEUTICALS LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.